Annual EBITDA
-$7.38 M
+$13.49 M+64.63%
31 December 2023
Summary:
GT Biopharma annual earnings before interest, taxes, depreciation & amortization is currently -$7.38 million, with the most recent change of +$13.49 million (+64.63%) on 31 December 2023. During the last 3 years, it has risen by +$17.59 million (+70.44%). GTBP annual EBITDA is now -145.23% below its all-time high of $16.32 million, reached on 31 December 2016.GTBP EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$3.41 M
+$299.00 K+8.06%
30 September 2024
Summary:
GT Biopharma quarterly earnings before interest, taxes, depreciation & amortization is currently -$3.41 million, with the most recent change of +$299.00 thousand (+8.06%) on 30 September 2024. Over the past year, it has dropped by -$995.00 thousand (-41.18%). GTBP quarterly EBITDA is now -112.31% below its all-time high of $27.71 million, reached on 30 June 2015.GTBP Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$12.35 M
-$995.00 K-8.76%
30 September 2024
Summary:
GT Biopharma TTM earnings before interest, taxes, depreciation & amortization is currently -$12.35 million, with the most recent change of -$995.00 thousand (-8.76%) on 30 September 2024. Over the past year, it has dropped by -$2.35 million (-23.51%). GTBP TTM EBITDA is now -149.83% below its all-time high of $24.78 million, reached on 30 September 2015.GTBP TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GTBP EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +64.6% | -41.2% | -23.5% |
| 3 y3 years | +70.4% | +37.5% | +74.5% |
| 5 y5 years | +97.0% | +88.4% | +68.1% |
GTBP EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +87.1% | <-9999.0% | +81.0% | -67.2% | +78.5% |
| 5 y | 5 years | at high | +97.0% | <-9999.0% | +88.4% | -67.2% | +78.5% |
| alltime | all time | -145.2% | +97.0% | -112.3% | +98.5% | -149.8% | +95.1% |
GT Biopharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.41 M(-8.1%) | -$12.35 M(+8.8%) |
| June 2024 | - | -$3.71 M(+63.7%) | -$11.35 M(+17.8%) |
| Mar 2024 | - | -$2.27 M(-23.5%) | -$9.63 M(+30.5%) |
| Dec 2023 | -$7.38 M(-64.6%) | -$2.96 M(+22.6%) | -$7.38 M(-26.1%) |
| Sept 2023 | - | -$2.42 M(+21.3%) | -$10.00 M(-30.9%) |
| June 2023 | - | -$1.99 M(>+9900.0%) | -$14.46 M(-6.4%) |
| Mar 2023 | - | -$15.00 K(-99.7%) | -$15.45 M(-26.0%) |
| Dec 2022 | -$20.88 M(-63.6%) | -$5.58 M(-19.0%) | -$20.88 M(-37.3%) |
| Sept 2022 | - | -$6.88 M(+131.0%) | -$33.30 M(+4.5%) |
| June 2022 | - | -$2.98 M(-45.2%) | -$31.87 M(-5.6%) |
| Mar 2022 | - | -$5.44 M(-69.8%) | -$33.75 M(-41.1%) |
| Dec 2021 | -$57.30 M(+129.4%) | -$18.00 M(+230.1%) | -$57.30 M(+18.2%) |
| Sept 2021 | - | -$5.45 M(+12.2%) | -$48.49 M(+7.8%) |
| June 2021 | - | -$4.86 M(-83.2%) | -$44.98 M(-14.9%) |
| Mar 2021 | - | -$28.98 M(+215.1%) | -$52.89 M(+111.8%) |
| Dec 2020 | -$24.98 M(-31.6%) | -$9.20 M(+372.9%) | -$24.98 M(+50.3%) |
| Sept 2020 | - | -$1.95 M(-84.8%) | -$16.61 M(-62.2%) |
| June 2020 | - | -$12.76 M(+1092.9%) | -$43.99 M(+31.2%) |
| Mar 2020 | - | -$1.07 M(+28.1%) | -$33.52 M(-8.2%) |
| Dec 2019 | -$36.52 M(-85.4%) | -$835.00 K(-97.2%) | -$36.51 M(-5.8%) |
| Sept 2019 | - | -$29.32 M(+1174.1%) | -$38.76 M(-84.1%) |
| June 2019 | - | -$2.30 M(-43.3%) | -$244.10 M(-1.2%) |
| Mar 2019 | - | -$4.05 M(+31.2%) | -$246.96 M(-1.2%) |
| Dec 2018 | -$250.06 M(+84.5%) | -$3.09 M(-98.7%) | -$250.06 M(-1.1%) |
| Sept 2018 | - | -$234.66 M(+4451.1%) | -$252.86 M(+74.3%) |
| June 2018 | - | -$5.16 M(-28.0%) | -$145.06 M(+2.7%) |
| Mar 2018 | - | -$7.16 M(+21.5%) | -$141.19 M(+4.1%) |
| Dec 2017 | -$135.57 M(-930.5%) | -$5.89 M(-95.4%) | -$135.57 M(+3.7%) |
| Sept 2017 | - | -$126.86 M(+9772.0%) | -$130.73 M(+2089.4%) |
| June 2017 | - | -$1.28 M(-16.4%) | -$5.97 M(+286.7%) |
| Mar 2017 | - | -$1.54 M(+45.7%) | -$1.54 M(-60.5%) |
| Dec 2016 | $16.32 M(-282.9%) | -$1.05 M(-49.6%) | -$3.91 M(-85.2%) |
| Sept 2016 | - | -$2.09 M(-166.6%) | -$26.44 M(+8.7%) |
| June 2016 | - | $3.14 M(-180.5%) | -$24.32 M(-9826.8%) |
| Mar 2016 | - | -$3.90 M(-83.5%) | $250.00 K(-89.3%) |
| Dec 2015 | -$8.93 M(+275.9%) | -$23.59 M(<-9900.0%) | $2.34 M(-90.6%) |
| Sept 2015 | - | $32.00 K(-99.9%) | $24.78 M(+4.2%) |
| June 2015 | - | $27.71 M(-1630.9%) | $23.79 M(-693.1%) |
| Mar 2015 | - | -$1.81 M(+57.3%) | -$4.01 M(+69.0%) |
| Dec 2014 | -$2.37 M(-440.6%) | -$1.15 M(+20.3%) | -$2.37 M(+78.2%) |
| Sept 2014 | - | -$957.00 K(+929.0%) | -$1.33 M(+154.2%) |
| June 2014 | - | -$93.00 K(-46.2%) | -$524.00 K(+6.9%) |
| Mar 2014 | - | -$173.00 K(+58.7%) | -$490.00 K(-170.4%) |
| Dec 2013 | $697.00 K(-119.9%) | -$109.00 K(-26.8%) | $696.00 K(+64.2%) |
| Sept 2013 | - | -$149.00 K(+152.5%) | $424.00 K(-154.6%) |
| June 2013 | - | -$59.00 K(-105.8%) | -$776.00 K(-60.3%) |
| Mar 2013 | - | $1.01 M(-365.9%) | -$1.95 M(-44.3%) |
| Dec 2012 | -$3.51 M(+12.5%) | -$381.00 K(-71.8%) | -$3.50 M(-15.9%) |
| Sept 2012 | - | -$1.35 M(+9.1%) | -$4.17 M(+56.0%) |
| June 2012 | - | -$1.24 M(+129.7%) | -$2.67 M(+39.8%) |
| Mar 2012 | - | -$538.00 K(-48.5%) | -$1.91 M(-38.8%) |
| Dec 2011 | -$3.12 M(+27.3%) | -$1.04 M(-815.1%) | -$3.12 M(+18.3%) |
| Sept 2011 | - | $146.00 K(-130.7%) | -$2.64 M(-22.1%) |
| June 2011 | - | -$475.00 K(-72.8%) | -$3.39 M(+35.8%) |
| Mar 2011 | - | -$1.75 M(+211.6%) | -$2.49 M(+2.1%) |
| Dec 2010 | -$2.45 M(+132.3%) | -$561.00 K(-7.0%) | -$2.44 M(-0.4%) |
| Sept 2010 | - | -$603.00 K(-244.3%) | -$2.45 M(+24.6%) |
| June 2010 | - | $418.00 K(-124.6%) | -$1.97 M(-23.6%) |
| Mar 2010 | - | -$1.70 M(+197.0%) | -$2.58 M(+144.1%) |
| Dec 2009 | -$1.05 M(+31.7%) | -$571.00 K(+379.8%) | -$1.05 M(+85.7%) |
| Sept 2009 | - | -$119.00 K(-37.0%) | -$568.00 K(+113.5%) |
| June 2009 | - | -$189.00 K(+7.4%) | -$266.00 K(+129.3%) |
| Mar 2009 | - | -$176.00 K(+109.5%) | -$116.00 K(-85.5%) |
| Dec 2008 | -$801.00 K(+259.2%) | -$84.00 K(-145.9%) | -$800.00 K(-40.1%) |
| Sept 2008 | - | $183.00 K(-569.2%) | -$1.33 M(-12.5%) |
| June 2008 | - | -$39.00 K(-95.5%) | -$1.52 M(+80.9%) |
| Mar 2008 | - | -$860.00 K(+38.9%) | -$843.00 K(+278.0%) |
| Dec 2007 | -$223.00 K(-90.6%) | -$619.00 K(+8742.9%) | -$223.00 K(-67.4%) |
| Sept 2007 | - | -$7000.00(-101.1%) | -$684.00 K(-31.3%) |
| June 2007 | - | $643.00 K(-367.9%) | -$996.00 K(-52.1%) |
| Mar 2007 | - | -$240.00 K(-77.8%) | -$2.08 M(-12.2%) |
| Dec 2006 | -$2.37 M(+54.3%) | -$1.08 M(+238.6%) | -$2.37 M(+21.4%) |
| Sept 2006 | - | -$319.00 K(-27.5%) | -$1.95 M(-0.1%) |
| June 2006 | - | -$440.00 K(-17.0%) | -$1.95 M(+6.7%) |
| Mar 2006 | - | -$530.00 K(-20.1%) | -$1.83 M(+19.2%) |
| Dec 2005 | -$1.53 M(+366.6%) | -$663.00 K(+107.2%) | -$1.53 M(+229.4%) |
| Sept 2005 | - | -$320.00 K(+0.9%) | -$466.00 K(-341.5%) |
| June 2005 | - | -$317.00 K(+34.9%) | $193.00 K(-11.9%) |
| Mar 2005 | - | -$235.00 K(-157.9%) | $219.00 K(+11.7%) |
| Dec 2004 | -$329.00 K | $406.00 K(+19.8%) | $196.00 K(-151.9%) |
| Sept 2004 | - | $339.00 K(-216.5%) | -$378.00 K(-53.2%) |
| June 2004 | - | -$291.00 K(+12.8%) | -$808.00 K(+8.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2004 | - | -$258.00 K(+53.6%) | -$745.00 K(+25.0%) |
| Dec 2003 | -$596.00 K(+12.7%) | -$168.00 K(+84.6%) | -$596.00 K(+32.2%) |
| Sept 2003 | - | -$91.00 K(-60.1%) | -$451.00 K(-22.5%) |
| June 2003 | - | -$228.00 K(+109.2%) | -$582.00 K(+29.0%) |
| Mar 2003 | - | -$109.00 K(+373.9%) | -$451.00 K(-14.7%) |
| Dec 2002 | -$529.00 K(-82.6%) | -$23.00 K(-89.6%) | -$529.00 K(-4.0%) |
| Sept 2002 | - | -$222.00 K(+128.9%) | -$551.00 K(-13.8%) |
| June 2002 | - | -$97.00 K(-48.1%) | -$639.00 K(-70.6%) |
| Mar 2002 | - | -$187.00 K(+315.6%) | -$2.17 M(-28.4%) |
| Dec 2001 | -$3.04 M(-29.0%) | -$45.00 K(-85.5%) | -$3.04 M(-30.8%) |
| Sept 2001 | - | -$310.00 K(-81.0%) | -$4.39 M(-14.4%) |
| June 2001 | - | -$1.63 M(+55.5%) | -$5.13 M(+13.5%) |
| Mar 2001 | - | -$1.05 M(-25.0%) | -$4.52 M(+5.5%) |
| Dec 2000 | -$4.28 M(+19.9%) | -$1.40 M(+33.3%) | -$4.28 M(+31.5%) |
| Sept 2000 | - | -$1.05 M(+2.5%) | -$3.26 M(+4.8%) |
| June 2000 | - | -$1.02 M(+25.8%) | -$3.11 M(-13.3%) |
| Mar 2000 | - | -$813.00 K(+118.5%) | -$3.58 M(-2.4%) |
| Dec 1999 | -$3.57 M(-35.1%) | -$372.00 K(-58.7%) | -$3.67 M(-26.6%) |
| Sept 1999 | - | -$900.00 K(-40.0%) | -$5.00 M(-13.8%) |
| June 1999 | - | -$1.50 M(+66.7%) | -$5.80 M(+11.5%) |
| Mar 1999 | - | -$900.00 K(-47.1%) | -$5.20 M(-10.3%) |
| Dec 1998 | -$5.50 M(+44.7%) | -$1.70 M(0.0%) | -$5.80 M(+20.8%) |
| Sept 1998 | - | -$1.70 M(+88.9%) | -$4.80 M(+11.6%) |
| June 1998 | - | -$900.00 K(-40.0%) | -$4.30 M(-6.5%) |
| Mar 1998 | - | -$1.50 M(+114.3%) | -$4.60 M(+17.9%) |
| Dec 1997 | -$3.80 M(-15.6%) | -$700.00 K(-41.7%) | -$3.90 M(-11.4%) |
| Sept 1997 | - | -$1.20 M(0.0%) | -$4.40 M(0.0%) |
| June 1997 | - | -$1.20 M(+50.0%) | -$4.40 M(-2.2%) |
| Mar 1997 | - | -$800.00 K(-33.3%) | -$4.50 M(-4.3%) |
| Dec 1996 | -$4.50 M(+9.8%) | -$1.20 M(0.0%) | -$4.70 M(-4.1%) |
| Sept 1996 | - | -$1.20 M(-7.7%) | -$4.90 M(+2.1%) |
| June 1996 | - | -$1.30 M(+30.0%) | -$4.80 M(+4.3%) |
| Mar 1996 | - | -$1.00 M(-28.6%) | -$4.60 M(+15.0%) |
| Dec 1995 | -$4.10 M(+192.9%) | -$1.40 M(+27.3%) | -$4.00 M(+17.6%) |
| Sept 1995 | - | -$1.10 M(0.0%) | -$3.40 M(+9.7%) |
| June 1995 | - | -$1.10 M(+175.0%) | -$3.10 M(+34.8%) |
| Mar 1995 | - | -$400.00 K(-50.0%) | -$2.30 M(+15.0%) |
| Dec 1994 | -$1.40 M(-12.5%) | -$800.00 K(0.0%) | -$2.00 M(+33.3%) |
| Sept 1994 | - | -$800.00 K(+166.7%) | -$1.50 M(+36.4%) |
| June 1994 | - | -$300.00 K(+200.0%) | -$1.10 M(-38.9%) |
| Mar 1994 | - | -$100.00 K(-66.7%) | -$1.80 M(0.0%) |
| Dec 1993 | -$1.60 M(+220.0%) | -$300.00 K(-25.0%) | -$1.80 M(+12.5%) |
| Sept 1993 | - | -$400.00 K(-60.0%) | -$1.60 M(+23.1%) |
| June 1993 | - | -$1.00 M(+900.0%) | -$1.30 M(+225.0%) |
| Mar 1993 | - | -$100.00 K(0.0%) | -$400.00 K(-20.0%) |
| Dec 1992 | -$500.00 K(0.0%) | -$100.00 K(0.0%) | -$500.00 K(0.0%) |
| Sept 1992 | - | -$100.00 K(0.0%) | -$500.00 K(0.0%) |
| June 1992 | - | -$100.00 K(-50.0%) | -$500.00 K(-350.0%) |
| Mar 1992 | - | -$200.00 K(+100.0%) | $200.00 K(-81.8%) |
| Dec 1991 | -$500.00 K(-200.0%) | -$100.00 K(0.0%) | $1.10 M(-168.8%) |
| Sept 1991 | - | -$100.00 K(-116.7%) | -$1.60 M(+220.0%) |
| June 1991 | - | $600.00 K(-14.3%) | -$500.00 K(-600.0%) |
| Mar 1991 | - | $700.00 K(-125.0%) | $100.00 K(-80.0%) |
| Dec 1990 | $500.00 K(0.0%) | -$2.80 M(-380.0%) | $500.00 K(+400.0%) |
| Sept 1990 | - | $1.00 M(-16.7%) | $100.00 K(>+9900.0%) |
| June 1990 | - | $1.20 M(+9.1%) | $0.00(-100.0%) |
| Mar 1990 | - | $1.10 M(-134.4%) | $500.00 K(0.0%) |
| Dec 1989 | $500.00 K(-600.0%) | -$3.20 M(-455.6%) | $500.00 K(-61.5%) |
| Sept 1989 | - | $900.00 K(-47.1%) | $1.30 M(+18.2%) |
| June 1989 | - | $1.70 M(+54.5%) | $1.10 M(+120.0%) |
| Mar 1989 | - | $1.10 M(-145.8%) | $500.00 K(-600.0%) |
| Dec 1988 | -$100.00 K(-150.0%) | -$2.40 M(-442.9%) | -$100.00 K(-116.7%) |
| Sept 1988 | - | $700.00 K(-36.4%) | $600.00 K(0.0%) |
| June 1988 | - | $1.10 M(+120.0%) | $600.00 K(+500.0%) |
| Mar 1988 | - | $500.00 K(-129.4%) | $100.00 K(-50.0%) |
| Dec 1987 | $200.00 K(-133.3%) | -$1.70 M(-342.9%) | $200.00 K(-113.3%) |
| Sept 1987 | - | $700.00 K(+16.7%) | -$1.50 M(+15.4%) |
| June 1987 | - | $600.00 K(0.0%) | -$1.30 M(+62.5%) |
| Mar 1987 | - | $600.00 K(-117.6%) | -$800.00 K(0.0%) |
| Dec 1986 | -$600.00 K(-25.0%) | -$3.40 M(-477.8%) | -$800.00 K(<-9900.0%) |
| Sept 1986 | - | $900.00 K(-18.2%) | $0.00(-100.0%) |
| June 1986 | - | $1.10 M(+83.3%) | -$500.00 K(-44.4%) |
| Mar 1986 | - | $600.00 K(-123.1%) | -$900.00 K(+12.5%) |
| Dec 1985 | -$800.00 K(-500.0%) | -$2.60 M(-750.0%) | -$800.00 K(-52.9%) |
| Sept 1985 | - | $400.00 K(-42.9%) | -$1.70 M(+88.9%) |
| June 1985 | - | $700.00 K(0.0%) | -$900.00 K(+125.0%) |
| Mar 1985 | - | $700.00 K(-120.0%) | -$400.00 K(-500.0%) |
| Dec 1984 | $200.00 K(-140.0%) | - | - |
| Dec 1984 | - | -$3.50 M(-391.7%) | $100.00 K(-97.2%) |
| Sept 1984 | - | $1.20 M(0.0%) | $3.60 M(+50.0%) |
| June 1984 | - | $1.20 M(0.0%) | $2.40 M(+100.0%) |
| Mar 1984 | - | $1.20 M | $1.20 M |
| Feb 1984 | -$500.00 K | - | - |
FAQ
- What is GT Biopharma annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for GT Biopharma?
- What is GT Biopharma annual EBITDA year-on-year change?
- What is GT Biopharma quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for GT Biopharma?
- What is GT Biopharma quarterly EBITDA year-on-year change?
- What is GT Biopharma TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for GT Biopharma?
- What is GT Biopharma TTM EBITDA year-on-year change?
What is GT Biopharma annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of GTBP is -$7.38 M
What is the all time high annual EBITDA for GT Biopharma?
GT Biopharma all-time high annual earnings before interest, taxes, depreciation & amortization is $16.32 M
What is GT Biopharma annual EBITDA year-on-year change?
Over the past year, GTBP annual earnings before interest, taxes, depreciation & amortization has changed by +$13.49 M (+64.63%)
What is GT Biopharma quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of GTBP is -$3.41 M
What is the all time high quarterly EBITDA for GT Biopharma?
GT Biopharma all-time high quarterly earnings before interest, taxes, depreciation & amortization is $27.71 M
What is GT Biopharma quarterly EBITDA year-on-year change?
Over the past year, GTBP quarterly earnings before interest, taxes, depreciation & amortization has changed by -$995.00 K (-41.18%)
What is GT Biopharma TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of GTBP is -$12.35 M
What is the all time high TTM EBITDA for GT Biopharma?
GT Biopharma all-time high TTM earnings before interest, taxes, depreciation & amortization is $24.78 M
What is GT Biopharma TTM EBITDA year-on-year change?
Over the past year, GTBP TTM earnings before interest, taxes, depreciation & amortization has changed by -$2.35 M (-23.51%)